Ciprofloxacin-resistant Salmonella enterica Typhimurium and Choleraesuis from pigs to humans, Taiwan – Research
We evaluated the disk susceptibility data of 671 nontyphoid Salmonella isolates collected from different parts of Taiwan from March 2001 to August 2001 and 1,261 nontyphoid Salmonella isolates from the National Taiwan University Hospital from 1996 to 2001. Overall, ciprofloxacin resistance was found in 2.7% (18/671) of all nontyphoid Salmonella isolates, in 1.4% (5/347) of Salmonella enterica serotype Typhimurium and in 7.5% (8/107) in S. enterica serotype Choleraesuis nationwide. MICs of six newer fluoroquinolones were determined for the following isolates: 37 isolates of ciprofloxacin-resistant (human) S. Typhimurium (N = 26) and Choleraesuis (N = 11), 10 isolates of ciprofloxacin-susceptible (MIC 0.12 [micro]g/mL). Sequence analysis of the gryA, gyrB, parC, parE, and acrR genes, ciprofloxacin accumulation, and genotypes generated by pulsed-field gel electrophoresis with three restriction enzymes (SpeI, XbaI, and BlnI) were performed. All 26 S. Typhimurium isolates from humans and pigs belonged to genotype I. For S. Choleraesuis isolates, 91% (10/11) of human isolates and 54% (7/13) of swine isolates belonged to genotype B. These two genotypes isolates from humans all exhibited a high-level of resistance to ciprofloxacin (MIC 16-64 mg/mL). They had two-base substitutions in the gyrA gene at codons 83 (Ser83Phe) and 87 (Asp87Gly or Asp87Asn) and in the parC gene at codon 80 (Ser80Arg, Ser80Ile, or Ser84Lys). Our investigation documented that not only did these two S. enterica isolates have a high prevalence of ciprofloxacin resistance nationwide but also that some closely related ciprofloxacin-resistant strains are disseminated from pigs to humans.
Infections caused by nontyphoid Salmonella in humans are increasingly frequent in developed and developing countries (1,2). The increasing rates of resistance to traditional anti-Salmonella agents (i.e., ampicillin, chloramphenicol, and trimethoprim-sulfamethoxazole) and extended-spectrum cephalosporins among these isolates have made treatment of invasive salmonellosis a clinical dilemma (3-6). Of particular concern is the emergence of fluoroquinolone resistance among nontyphoid Salmonella and the occurrence of outbreaks caused by some resistant clones, since this class of antimicrobial agents constitutes the drug of choice for treating potentially life-threatening Salmonella infections caused by the multidrug-resistant strains in adult persons (7 16). Moreover, cases of treatment failure due to fluoroquinolone resistance in Salmonella strains have been reported (17-19).
Researchers have increasingly reported that widespread use of fluoroquinolones in food animals leads to the rapid emergence and dissemination of resistant Salmonella infections to humans, particularly in developing countries (4,8,20-23). In Taiwan, Chiu et al. reported that resistance to ciprofloxacin among S. enterica Choleraesuis isolates first appeared in 2000 and [less than or equal to] 60% of the isolates recovered from two hospitals in northern Taiwan in the third quarter of 2001 were resistant to ciprofloxacin (14). Molecular investigation clearly demonstrated that the primary sources of these resistant strains were herds of pigs.
To better understand the prevalence of nationwide resistance and the probable dissemination of ciprofloxacin-resistant nontyphoid Salmonella isolates, particularly S. Typhimurium and Choleraesuis, we determined the mechanisms of quinolone resistance and the genotypes of ciprofloxacin-resistant isolates from humans and pigs, collected in different parts of Taiwan. This study is part of the Surveillance from Multicenter Antimicrobial Resistance in Taiwan (SMART) programs conducted in 2001.
Materials and Methods
A total of 671 nontyphoid Salmonella isolates were collected for the study. These isolates were recovered from various clinical specimens of patients treated at 11 major hospitals (bed capacities from 800 to 2,000) in different regions of Taiwan. These hospitals included the National Taiwan University Hospital (NTU; hospital A), Taipei; Taipei Veterans General Hospital (hospital B), Taipei; Mackay Memorial Hospital (hospital C), Taipei; Tri-service General Hospital (hospital D), Taipei; Taichung Veterans General Hospital (hospital E), Taichung; China Medical College Hospital (hospital F), Taichung; National Cheng-Kung University Hospital (hospital G), Tainan; Chi-Mei Medical Center (hospital H), Tainan; Kaohsiung Veterans General Hospital (hospital I), Kaohsiung; and Tzu-Chi General Hospital, Hualien (hospital J). Of the 671 isolates tested, 429 (64%) were recovered from stool samples, 141 (21%) from blood, and the rest from various body fluids.
Disk diffusion susceptibility results on these isolates were also provided by the hospitals and evaluated. Organisms were categorized as susceptible or resistant (including intermediate isolates) to the antimicrobial agents tested on the basis of the guidelines provided by the National Committee for Clinical Laboratory Standards (NCCLS) (24). Isolates of Salmonella serogroups B and C were further identified to the serotype level, according to the Kauffman and White scheme, by using somatic and flagellar antigens (Denka Seiken Co., Ltd., Tokyo, Japan) and also by conventional methods and the Phoenix System (panel type, NMIC/ID4) (Becton Dickson, Sparks, MD) at hospital A (25). Table 1 shows the number of isolates of nontyphoid Salmonella, S. Typhimurium, and S. Choleraesuis, and the ciprofloxacin resistance for the two serotypes of S. enterica isolates recovered from the 11 hospitals.
A total of 13 isolates of S. Choleraesuis and two isolates of S. Typhimurium recovered from pigs raised in southern (N = 11) and central (N = 4) Taiwan from 1997 to 2002 were also collected for study. Of the 15 isolates, 2 each were collected in 1997, 1999, and 2001 and 3 each in 1998, 2000, and 2002. These isolates were collected from various visceral organs (lungs, liver, or spleen) or from stool specimens of pigs that died of septicemia. All the isolates were stored at -70[degrees]C in trypticase soy broth (Difco Laboratories, Detroit, MI) supplemented with 15% glycerol before being further tested. S. Choleraesuis ATCC 13312 and S. Typhimurium ATCC 14028 were used as control strains.
Prevalence of Resistance at Hospital A
To determine the prevalence of antimicrobial resistance among nontyphoid Salmonella, we analyzed the disk diffusion susceptibility results of these organisms to ampicillin, cefotaxime/ceftriaxone, chloramphenicol, trimethoprim-sulfamethoxazole, and ciprofloxacin recovered from 1996 to 2001 at hospital A. Isolates of Salmonella serogroups B and C resistant to ciprofloxacin (by the disk diffusion method) were further identified to the serotype level by the methods mentioned above.
Antimicrobial Susceptibility Testing
Of the 671 isolates collected from 11 medical centers in 2001, 37 ciprofloxacin-resistant (by the disk diffusion method) S. Typhimurium (N = 26) and S. Choleraesuis (N = 11) isolates and 10 randomly selected ciprofloxacin-susceptible (by the disk diffusion method) isolates of these two serotypes were tested for susceptibility to six fluoroquinolones (ciprofloxacin, levofloxacin, moxifloxacin, trovafloxacin, gatifloxacin, and garenoxacin) to determine their MICs by using the agar dilution method according to the guidelines established by NCCLS (26). The 37 ciprofloxacin-resistant isolates included 13 isolates from the 2001 SMART program (5 S. Typhimurium isolates and 8 S. Choleraesuis isolates) and 24 recovered from 1996 to 2000 at hospital A (21 S. Typhimurium isolates and 3 S. Choleraesuis isolates). These ciprofloxacin-resistant isolates were recovered from 29 patients. Six patients (patients 9, 10, 11, 15, 29, and 32) had isolates that were recovered after >7 days from various clinical specimens. The patients’ ages ranged from <1 year to 84 years (mean 31 years); those <2 years of age were predominant (47%) among patients with S. Typhimurium isolations. None of the patients with S. Choleraesuis bacteremia were <16 years. Among the 37 human isolates of ciprofloxacin-resistant nontyphoid Salmonella isolates, 13 (3 of S. Typhimurium and 10 of S. Choleraesuis) were recovered from blood specimens of 12 patients with bloodstream infections. The rest of the isolates were recovered from stool or urine specimens.
Dilution susceptibilities to the aforementioned fluoroquinolones were also performed for the 15 isolates from pig herds, according to the NCCLS guidelines (26).
PCR Amplification and DNA Sequencing of gyrA, gyrB, parC, parE, and acrR
The sequences of the primers for the polyermase chain reaction (PCR) amplification of gryA, gyrB, parC, parE, and acrR have been previously described (27-30). The preparation of the template DNA and the determination of sequences of each gene followed the procedures described previously (27-29). The sequences of the quinolone resistance-determining regions (QRDRs) were determined to be between amino acids 54 and 171 of gyrA, 397 and 520 of gyrB, 12 and 130 of parC, and 421 and 524 of parE.
The accumulation of ciprofloxacin, with or without 100 mM carbonyl cyanide m-chlorophenylhydrazone, was determined for two ciprofloxacin-resistant strains and one ciprofloxacin-susceptible S. Typhimurium (ciprofloxacin MIC = 0.06 [micro]g/mL) as described previously (28,29). These experiments were performed twice to ensure reproducibility.
Genotyping of the human ciprofloxacin-resistant S. Typhimurium (N = 26) and Choleraesuis (N = 11) isolates, the 10 human ciprofloxacin-susceptible isolates of the two serotypes, and the 15 isolates from pigs was determined by the pulsotypes generated by pulsed-field gel electrophoresis (PFGE). The DNA extraction and purification were also carried out as described previously (31,32). The DNA was digested by the restriction enzymes SpeI, XbaI, and BlnI (9,16,23,32), and the restriction fragments were separated in a CHEF-DRIll unit (Bio-Rad, Hercules, CA). Interpretation of the PFGE profiles followed the description by Tenover et al. (33). Isolates belonging to the similar pulsotypes (within six band differences) by each of the three restriction enzymes were defined as the same genotypes (closely related clusters). Isolates with identical pulsosubtypes (no band differences) by the three restriction enzymes were defined as the same genosubtypes (clones).
Nationwide Resistance in 2001
The rates of ciprofloxacin resistance among isolates of nontyphoid Salmonella, S. Typhimurimn, and S. Choleraesuis from the 11 hospitals, stratified by region of Taiwan, is shown in Table 1. Overall, ciprofloxacin resistance was found in 2.7% (18/671) of all nontyphoid Salmonella isolates from humans, 1.4% in S. Typhimurium and 7.5% in S. Choleraesuis nationwide (Table 1). Among S. Choleraesuis isolates, the highest rate of ciprofloxacin resistance was found in hospital B (28.5%) and southern region of Taiwan (9.5%). Among S. Typhimurium isolates, the highest rate of ciprofloxacin resistance was found in hospital D (25.0%) and in the northern region of Taiwan (3.5%). Nontyphoid Salmonella isolates recovered from patients in eastern region of Taiwan were all susceptible to ciprofloxacin. Rates of resistance to ampicillin and chloramphenicol were higher in eastern Taiwan than those from other regions of Taiwan. Resistance to cefotaxime (three hospitals tested ceftriaxone instead of cefotaxime) among all nontyphoid Salmonella isolates was low (<1%). However, 6% and 4% of S. Choleraesuis isolates recovered from central and southern Taiwan, respectively, were resistant to cefotaxime (ceftriaxone).
Prevalence of Ciprofloxacin Resistance at Hospital A
The annual number of nontyphoid Salmonella isolates (Salmonella group B and Salmonella group C) ranged from 294 in 1996 (182 and 46, respectively) to 90 in 2001 (76 and 8, respectively). Overall, the rate of ciprofloxacin resistance among nontyphoid Salmonella isolates was 2.1%. For Salmonella group B isolates, the rates of ciprofloxacin resistance were high (6% to 9%) during 1996 and 1997, reached a trough in 1999 (3%), and increased gradually in the following 2 years (4% in 2000 to 5% in 2001). Annual rates of resistance to ciprofloxacin among Salmonella group C isolates fluctuated during the same 6-year period (data not shown). In 1996, 1998, and 2001, none of the isolates were resistant to ciprofloxacin, and the highest rate of ciprofloxacin resistance was found in 2000 (13%).
The annual rates of resistance to ampicillin, cefotaxime, chloramphenicol, and trimethoprim-sulfamethoxazole among all nontyphoid Salmonella isolates, Salmonella group B, and Salmonella group C at hospital A from 1996 to 2001 were evaluated. Overall, the prevalence of resistance to cefotaxime among these isolates was low (0% to 4%). Rates of resistance to ampicillin, chloramphenicol, and trimethoprim-sulfamethoxazole among all nontyphoid Salmonella isolates declined gradually from 1996 (64%, 64%, and 42%, respectively) to 2000 (47%, 52%, and 34%, respectively). In 2001, however, rates of resistance to ampicillin (73%) and chloramphenicol (76%) increased but that of trimethoprim-sulfamethoxazole (28%) continued to decrease. A similar scenario was found among Salmonella group B isolates. For Salmonella group C isolates, rates of resistance to these agents also fluctuated during the study period.
Antimicrobial Susceptibilities of Human Ciprofloxacin-resistant Isolates
All of the human ciprofloxacin-resistant isolates were highly resistant to ampicillin (MIC [greater than or equal to] 128 [micro]g/mL), chloramphenicol (MIC [greater than or equal to] 128 [micro]g/mL), and trimethoprim-sulfamethoxazole ([greater than or equal to] 128 [micro]g/mL) but susceptible to cefotaxime (MIC 0.06-8 [micro]g/mL). These ciprofloxacin-resistant isolates from humans all exhibited high-levels of resistance to ciprofloxacin (MIC 8 to 64 [micro]g/mL), levofloxacin (MIC 32-64 [micro]g/mL), moxifloxacin (MIC 32-28 [micro]g/mL), gatifloxacin (MIC 16-32 [micro]g/mL), garenoxacin (MIC 16-64 [micro]g/mL), and trovafloxacin (MIC 8-64 [micro]g/mL).
Fluoroquinolone Susceptibilities among Swine S. Choleraesuis Isolates
All 15 isolates of S. Typhimurium and Choleraesuis from pigs had reduced susceptibility to ciprofloxacin (MIC [greater than or equal to] 0.125 [micro]g/mL). Eight of the 15 isolates (53%) were susceptible or intermediate to ciprofloxacin according to the NCCLS breakpoint recommendation (MIC [less than or equal to] 2 [micro]g/mL). Seven (47%) isolates had high ciprofloxacin MICs (MIC [greater than or equal to] 64 [micro]g/mL); these seven isolates were also highly resistant to five other newer fluoroquinolones: levofloxacin (MIC 32-64 [micro]g/mL), moxifloxacin (MIC 32-128 [micro]g/mL), trovafloxacin (MIC 64 [micro]g/mL), gatifloxacin (MIC 16-32 [micro]g/mL), and garenoxacin (MIC 32-64 [micro]g/mL).
Nucleotide Sequence Analysis
Of human ciprofloxacin-resistant S. Typhimurium isolates, all were associated with two-base substitutions in the QRDR of gyrA at codon 83 (Ser83Phe) (TCC[right arrow]TTC) and 87 (Asp87Gly) (GAC[right arrow]GGC), and either Ser80Arg or Glu84Lys in the QRDR of the parC gene (Table 2). One base substitution in the QRDR of gyrA (Ser83Tyr or Ser83Phe) was found in ciprofloxacin-susceptible isolates. One isolate had a mutation in the QRDR of the gyrB gene, but none had mutations in the QRDR of the parE gene. None of the S. Typhimurium isolates, including ciprofloxacin-susceptible or -resistant isolates, had mutations in the acrR genes.
Of human ciprofloxacin-resistant S. Choleraesuis, all were associated with two-base substitutions in the QRDR of the gyrA gene at codon 83 (Ser83Phe) and 87 (Asp87Asn), Ser80Ile in the QRDR of the parC gene, and Gln78Stp in the QRDR of the acrR gene (Table 3). None of these isolates had mutations in the QRDR of the gyrB or parE genes. One base substitution in the QRDR of the gyrA (Asp87Asn) was found in the ciprofloxacin-susceptible isolates.
Of pig herd ciprofloxacin-resistant S. Typhimurium isolates (N = 2), both had a mutation in the QRDR of the gyrA and parC genes, respectively (Table 2). None of these isolates had mutations in the QRDR of the gyrB, parE, or arcR genes. Among pig herd ciprofloxacin-resistant S. Choleraesuis isolates, all had two mutations in the QRDR of gyrA (Ser83Phe plus Asp87Asn or Asp87Gly) and one mutation in pare (Ser80Ile) and arcR (Gln78Stp) (Table 3).
PFGE Analysis and Genotypes
All of the ciprofloxacin-resistant S. Typhimurium isolates from humans had the same pulsotype (pulsotype S) when the SpeI restriction enzyme was used. Figures 1 and 2 illustrate the pulsotypes and pulsosubtypes of S. Typhimurium (Figures 1A and 1B) and S. Choleraesuis (Figures 2A, 2B, and 2C) isolates by XbaI and BlnI. Using XbaI and BlnI, we observed six and eight pulsosubtypes, respectively, for S. Typhimurium isolates. Among S. Choleraesuis isolates, one pulsotype (x) and one pulsosubtype (x-1) were observed when the XbaI restriction enzyme was used, and two pulsotypes (a and b) with six pulsosubtypes (b-1 to b-6) were observed when the BlnI restriction enzyme was used. Using the three restriction enzymes, we found that all ciprofloxacin-susceptible isolates of S. Typhimurium and Choleraesuis had different genosubtypes (clones).
[FIGURES 1-2 OMITTED]
Among human ciprofloxacin-resistant S. Typhimurium isolates, all were closely related (genotype I) and belonged to 11 genosubtypes (genosubtypes Ia to Ik). Among the 11 genosubtypes, Ia (4 isolates), Ic (5 isolates), and Id (6 isolates) predominated. The five ciprofloxacin-susceptible isolates belonged to four genotypes (II-V) (Table 2). None of the genotypes among the S. Typhimurium isolates studied were identical to those of DT104.
Of human S. Choleraesuis isolates, 91% (10 of the 11 isolates) belonged to genotype B, which was different from those of the five ciprofloxacin-susceptible isolates from humans (genotypes C to G). None of the six genosubtypes (B1 to B6) of the genotype B isolates was predominant. Two isolates collected within 7 days of one another from patient 4 had identical genosubtypes (B2), but those from patient 7 had differing genosubtypes (B4 and B5) (Table 3).
Seven (54%) of the 13 swine S. Choleraesuis isolates belonged to genotype B (Table 3). Among the six genosubtypes of genotype B, two genosubtypes (B2 and B5) were also found in human isolates. Two swine isolates that showed descreased susceptibility to ciprofloxacin (MICs, 0.5 [micro]g/mL and 2 [micro]g/mL, respectively) also belonged to genotype B (genosubtypes B7 and B 10, respectively).
Evidence for Active Efflux
Ciprofloxacin uptake appeared to be remarkably low in the two ciprofloxacin-resistant genotypes (genosubtypes Ia and B1) (Figure 3). A rapid increase in cell-associated ciprofloxacin uptake among isolates belonging to the genosubtypes was evident after addition of carbonyl cyanide m-chlorophenylhydrazone (CCCP), a proton motive force uncoupler.
[FIGURE 3 OMITTED]
This report describes the rates of antimicrobial resistance among nontyphoid Salmonella isolates in a university hospital during a 6-year period. Furthermore, it characterizes the nationwide dissemination of ciprofloxacin-resistant strains of S. Typhimurium and Choleraesuis. Our observations in Taiwan suggest five important facets: First, ciprofloxacin resistance among our nontyphoid Salmonella from humans was high (2.7%), particularly among human S. Choleraesuis isolates. Furthermore, a previous study found a remarkably high incidence (57%, 12 of 21 isolates) of S. Choleraesuis at two major teaching hospitals in northern Taiwan in the second to third quarters of 2001 (14). This observation contrasts greatly with our findings (7.7%, 2 of 25 isolates, from four hospitals in northern Taiwan, or 7.5% nationwide from March 2001 to August 2001) (14).
Second, nearly all ciprofloxacin-resistant S. Choleraesuis isolates from humans and pigs collected in 1999-2002 were closely related to one another (genotype B) and differed from those found in pigs in 1997-1998 (these isolates had highly diverse genotypes). These findings suggest that nationwide dissemination of S. Choleraesuis isolates from pigs to humans occurred from 1999 to 2002. Two isolates (AC-6 and AC-10) of S. Choleraesuis from pigs had reduced susceptibility to ciprofloxacin (MICs, 0.5 [micro]g/mL and 2 [micro]g/mL, respectively). They had an identical genotype (genotype B) to that of most of the epidemic strains found in humans and pigs. These strains had high-level ciprofloxacin resistance (MIC 16 to 64 [micro]g/mL). This indicates that the swine isolates with reduced susceptibility to ciprofloxacin might be an ancestor (a unique clone line) of the isolates that are highly resistant to ciprofloxacin and which have spread among herbs and humans nationwide (23,27).
Third, the S. Typhimurium strains (genotype I) with high-level fluoroquinolone resistance have been widely disseminated in humans in Taiwan since 1996. Strains belonging to genotype I and the other genotypes found in this study were domestically acquired and were not related to the clones of DT104, which were already disseminated throughout Europe and the United States (15,23). In 1998, one isolate exhibiting genotype I (genosubtype Ic) was isolated from a pig from southern Taiwan. Further studies on S. Typhimurium isolates from animals should be conducted to identify the primary source of the epidemic genotype strains.
Fourth, an increasing prevalence of resistance to ampicillin and chloramphenicol over time was observed in human S. Typhimurium isolates at hospital A. The spread of third-generation cephalosporin-resistant isolates harboring plasmid-mediated CMY-2 like cephalosporinase among S. Typhimurium isolates has been previously reported in Taiwan (6). Although all of the highly ciprofloxacin-resistant isolates in our study were susceptible to cefotaxime, according to NCCLS guidelines (24), five isolates from four patients with high cefotaxime MICs (MIC 4-8 [micro]g/mL) is noteworthy. The emergence of decreased susceptibility to cefotaxime, along with the preexisting ciprofloxacin resistance among nontyphoid Salmonella isolates, particularly those causing bloodstream infection, makes antimicrobial therapy more complicated.
Finally, rates of resistance varied geographically; higher rates of resistance to ampicillin and chloramphenicol were found in the eastern region of Taiwan. However, none of the nontyphoid Salmonella isolates collected in the eastern region of Taiwan was resistant to ciprofloxacin.
S. Typhimurium and S. Choleraesuis isolates with high levels of resistance to ampicillin, chloramphenicol, trimethoprim-sulfamethoxazole, cipro-floxacin, and other newer fluoroquinolones were rarely previously reported (2,19,28,30,34). In most gram-negative bacteria, including Salmonella, a high-level of fluoroquinolone resistance is related to the presence of multiple mutations in the QRDRs of the genes, particularly in the gyrA and parC genes (8,13,14,19,27,28,35).
Additional resistance mechanisms, such as decreased cell envelope permeability (loss of outer membrane porins or alterations of the lipopolysaccharide), decreased cellular accumulation of quinolones involving the major multidrug active efflux pump (AcrAB), or the presence of integrons, can also be responsible for fluoroquinolones resistance and resistance to a wide range of antimicrobial agents (31,35-39). Mutations in the acrR (regulator/repressor) gene are partly responsible for fluoroquinolone resistance in Escherichia coli (29). In our study, the two major genotypes (genotypes I and B) of ciprofloxacin-resistant isolates had both mutations in the gyrA (at least two mutations) and parC (at least one mutation) genes. The addition of CCCP, resulted in an increase in cell-associated ciprofloxacin uptake. This indicated that an active efflux contributed to fluoroquinolone resistance (28 31). In our study, acrR mutations were found in ciprofloxacin-resistant S. Choleraesuis, but not in Typhimurium, isolates. This finding is consistent with that of previous reports (30). Further studies are warranted to add clarification to the complexity of the mechanisms of high-level resistance among S. Typhimurium and Choleraesuis isolates.
PFGE analysis using restriction enzyme XbaI is a well-established method for epidemiologic typing of the Salmonella species (9,16,23,32). However, PFGE patterns by XbaI for most ciprofloxacin-resistant isolates investigated, including S. Choleraesuis isolates from human and animal origins, were indistinguishable. This scenario was also found in PFGE patterns for human S. Typhimurium isolates. When BlnI was added, the discriminatory power of pulsotyping improved among these ciprofloxacin-resistant isolates. Genotyping by using pulsotypes generated by XbaI and BlnI clearly demonstrated that several ciprofloxacin-resistant clones (particularly, genosubtypes Ia, Ic, and Id of S. Typhimurium) had disseminated to humans in Taiwan. Furthermore, some genosubtypes of ciprofloxacin-resistant S. Choleraesuis were found only in humans, and some were found only in pigs; however, two clones (genosubtypes B2 and B5) were found in both humans and pigs.
Research studies have provided evidence that antimicrobial agents used in agriculture and closely related agents used in human medicine have been exerting selective pressure on their target bacteria, particularly Salmonella, Campylobacter, and Escherichia coli (1,20,40). In Taiwan, quinolones (e.g., enrofloxacin) have been used in animals and humans (from nalidixic acid to the latest fluoroquinolone moxifloxacin) for >30 years. A governmental survey among farmers and feed mill operators in 1999 indicated that 40% of farmers and 50% of feed mill operators used quinolone agents (particularly enrofloxacin) on their flocks or herds of pigs for growth promotion or therapeutic purposes (41). Previous investigations demonstrated that >90% of Campylobacter species and 6% of E. coli from chickens were resistant to ciprofloxacin (41,42). When the selective pressure of quinolones persisted, isolates, or some clones with reduced susceptibility (a single gyrA mutation) to quinolones, might develop full resistance (two gyrA mutations or multiple mutations in the QRDRs of other genes) in animals or humans and could probably jump from animals to humans (14,27). Our observations and findings from Chiu et al. indicate that outbreak-associated human Salmonella strains with high-level ciprofloxacin resistance might have emerged several years ago, similar to strains with antibiotypes of reduced susceptibility, but with identical genotypes, in humans or animals (14).
In conclusion, our investigation documented that S. Typhimurium and S. Choloraesuis isolates, which are highly fluoroquinolone-resistant and multidrug-resistant, have become widespread pathogens in Taiwan. The recent occurrence of ciprofloxacin resistance among Salmonella in animals, and its nationwide spread, is of particular concern. The remaining therapeutic options available to veterinarians and physicians for treatment of extraintestinal salmonellosis and other invasive infections include only third-generation cephalosporins. However, ciprofloxacin-resistant isolates, with reduced susceptibility to cefotaxime, have already emerged in Taiwan. Restricted use of quinolones in animal husbandry and active surveillance of quinolone resistance among Salmonella are crucial mitigation efforts to reduce selection and clonal spread of quinolone-resistant Salmonella.
Table 1. Number of ciprofloxacin-resistant nontyphoid Salmonella,
S. enterica Typhimurium, and S. enterica Choleraesuis isolates
from patients treated at 11 major teaching hospitals in different
regions of Taiwan, March 2001-August 2001
% (no. ciprofloxacin-resistant
isolates/no. total isolates) of
Hospital of total nontyphoid Salmonella
Northern region 4.3 (7/231)
A 0.0 (0/100)
B 8.2 (4/49)
C 1.7 (1/60)
D 9.1 (2/22)
Central region 3.9 (6/154)
E 5.3 (3/57)
F 7.7 (3/97)
Southern region 2.0 (5/255)
G 0.0 (0/99)
H 2.3 (2/86)
I 4.3 (3/70)
J 0.0 (0/31)
Total 2.7 (18/671)
% (no. ciprofloxacin-resistant isolates
/no. total isolates) of ciprofloxacin-
resistant isolates, by serotype
Hospital Typhimurium Choleraesuis Others
Northern region 3.5 (3/85) 7.7 (2/26) 1.7 (2/120)
A 0.0 (0/40) 0.0 (0/13) 0.0 (0/47)
B 0.0 (0/19) 28.5 (2/7) 8.7 (2/23)
C 5.6 (1/18) 0.0 (0/3) 0.0 (0/39)
D 25.0 (2/8) 0.0 (0/3) 0.0 (0/11)
Central region 2.4 (2/85) 6.1 (2/33) 5.6 (2/36)
E 2.8 (1/36) 7.1 (1/7) 7.1 (1/14)
F 2.0 (1/49) 3.8 (1/26) 4.5 (1/22)
Southern region 0.0 (0/155) 9.5 (4/42) 1.7 (1/58)
G 0.0 (0/67) 0.0 (0/11) 0.0 (0/21)
H 0.0 (0/55) 11.8 (2/17) 0.0 (0/14)
I 0.0 (0/33) 14.3 (2/14) 4.3 (1/23)
J 0.0 (0/22) 0.0 (0/6) 0.0 (0/3)
Total 1.4 (5/347) 7.5 (8/107) 2.3 (5/217)
Table 2. Characteristics of Salmonella enterica serotype
Typhimurium isolates from humans (a) and pigs, (b) Taiwan
Ciprofloxacin MIC Asp87Gly Asp87Asn Ser83Phe
susceptibility (N) ([micro]g/mL) (N) (N) (N)
Resistant (26) 16-64 24 2 0
Susceptible (5) 0.03-0.25 0 0 1
Resistant (2) 128 2 0 0
parC gene acrR gene
Ciprofloxacin Ser83Tyr Ser80Arg Glu84Lys Gln78Stp
susceptibility (N) (N) (N) (N) (N)
Resistant (26) 0 24 2 0
Susceptible (5) 2 0 0 0
Resistant (2) 0 2 0 0
Ciprofloxacin Arg107Cys Genotype:
susceptibility (N) (N) genosubtype
Resistant (26) 0 I (26), Ia, (4),
Ic (5), Id (6),
Ie (1), If (1),
Ig (2), Ih (1),
Ii (1) Ij (1), Ik
(2), I1 (1)
Susceptible (5) 0 IIa (1), IIb (1),
III (1), IV (1),
Resistant (2) 0 I (2): Ic (1),
(a) N = 31.
(b) N = 2.
Table 3. Characteristics of Salmonella enterica serotype Choleraesuis
isolates from humans (a) and pigs (b) in Taiwan
Ciprofloxacin MIC Asp87Asn Ser83Phe Asp87Asn
susceptibility (N) ([micro]g/mL) (N) (N) (N)
Resistant (11) 16-64 11 0 0
Susceptible (5) 0.03-0.25 0 0 1
Resistant (5) 64 5 5 0
Susceptible or 0.5-2 0 1 1
gyrA gene parC gene acrR gene
Ciprofloxacin Ser83Tyr Asp87Gyr Ser80Ile Gln78Stp
susceptibility (N) (N) (N) (N) (N)
Resistant (11) 0 0 0 0
Susceptible (5) 0 0 0 0
Resistant (5) 0 0 5 5
Susceptible or 2 4 0 0
Ciprofloxacin Arg107Cys Genotype:
susceptibility (N) (N) genosubtype (N)
Resistant (11) 0 A (1); B (10): B1
(2), B2 (2), B3
(2), B4 (1), B5
Susceptible (5) 0 C (1), D (1), E
(1), F (1), G (1)
Resistant (5) 0 0 B (5): B2 (1),
B5 (1), B8 (1),
Susceptible or 0 B (2): B7 (1),
intemtediate (8) B10 (1); H (1), I
(1), J(3), K(1)
(a) N = 16.
(b) N = 13.
This work was partly supported by a research grant NSC91-2314-B002-171 from the National Science Council, Taiwan.
(1.) Tauxe RV. Emerging food-borne diseases: an evolving public health challenge. Emerg Infect Dis 1997;3:425-34.
(2.) Ho YH, Hsueh PR, Lu CY, Chen RT, Yang TY, Yang SC, et al. Serogroups and antimicrobial susceptibility of non-typhoid Salmonella isolates in a medical center. J Microbiol Immunol Infect 2003. In press.
(3.) Lee LA, Puhr ND, Maloney EK, Bean NH, Tauxe RV. Increase in antimicrobial-resistant Salmonella infections in the United States, 1989-1990. J Infect Dis 1994;170:128-34.
(4.) Angulo FJ, Johnson KR, Tauxe RV, Cohen ML. Origins and consequences of antimicrobial-resistant nontyphoidal Salmonella: implications for the use of fluoroquinolones in food animals. Microb Drug Resist 2000;6:77-83.
(5.) Hsueh PR, Liu CY, Luh KT. Current status of antimicrobial resistance in Taiwan. Emerg Infect Dis 2002;8:132-7.
(6.) Yan JJ, Ko WC, Chiu CH, Tsai SH, Wu HM, Wu JJ. Emergence of ceftriaxone-resistant Salmonella isolates and the rapid spread of plasmid-encoded CMY-2-like cephalosporinase, Taiwan. Emerg Infect Dis 2003;9:323-8.
(7.) Threlfall EJ,. Ward LR,. Skinner JA,. Graham A. Antimicrobial drug resistance in non-typhoidal salmonellas from humans in England and Wales in 1999: decrease in multiple resistance in Salmonella enterica serotypes Typhimurium, Virchow, and Hadar. Microb Drug Resist 2000;6:319-25.
(8.) Carnevale R, Molbak K, Bager F, Aarestrup FM. Fluoroquinolone resistance in Salmonella: a Web discussion. Clin Infect Dis 2000;31:128-30.
(9.) Molbak K, Baggesen DL, Aarestrup FM, Ebbesen JM, Engberg J, Frydendahl K, et al. An outbreak of multidrug-resistant, quinolone-resistant Salmonella enterica serotype Typhimurium DT 104. N Engl J Med 1999;341:1420-5.
(10.) Herikstad H, Hayes P, Mokhtar M, Fracaro ME, Threlfall EJ, Angulo FJ. Emerging quinolone-resistant Salmonella in the United States. Emerg Infect Dis 1997;3:371-2.
(11.) Hakanen A, Siitonen A, Kotilaninen P, Huovinen E Increasing fluoroquinolone resistance in salmonella serotypes in Finland during 1995-1997. J Antimicrob Chemother 1999;43:145-8.
(12.) Leegaard TM, Caugnat DA, Froholm LO, Hoiby EA, Lassen J. Emerging antibiotic resistance in Salmonella Typhimurium in Norway. Epidemiol Infect 2000;125:473-80.
(13.) Hakanen A, Kotilainen P, Huovinen P, Helenius H, Siitonen A. Reduced fluoroquinolone susceptibility in Salmonella enterica serotypes in travelers returning from Southern Asia. Emerg Infect Dis 2001;7:996-1003.
(14.) Chiu CH, Wu TL, Su LH, Chu C, Chia JH, Kuo AJ, et al. The emergence in Taiwan of fluoroquinolone resistance in Salmonella enterica serotype Choleraesuis. N Engl J Med 2002;346:413-9.
(15.) Glynn MK, Bopp C, Dewitt W. Dabney P, Mokhtar M, Angulo FJ. Emergence of multidrug-resistant Salmonella enterica serotype Typhimurium DT104 infections in the United States. N Engl J Med 1998;338:1333-8.
(16.) Olsen SJ, DeBess EE, McGiven TE Marano N, Eby T, Mauvais S, et al. A nosocomial outbreak of fluoroquinolone-resistant Salmonella infection. N Engl J Med 2001;344:1527-9.
(17.) Piddock LJV, Griggs DJ, Hall MC, Jin YF. Ciprofloxacin resistance in clinical isolates of Salmonella Typhimurium obtained from two patients. Antimicrob Agents Chemother 1993;37:662-6.
(18.) Heisig P. High level fluoroquinolone resistance in Salmonella Typhimurium isolates due to alterations in both gyrA and gyrB genes. J Antimicrob Chemother 1993;32:367-77.
(19.) Nakaya H, Yasuhara A, Yoshimura K, Oshihoi Y, Izumiya H, Watnanbe H. Life-threatening diarrhea from fluoroquinolone-resistant Salmonella enterica Typhimurium with mutations in both gvrA and parC. Emerg Infect Dis 2003;9:255-7.
(20.) Witte W. Medical consequences of antibiotic use in agriculture. Science 1998;279:996-7.
(21.) Threlfall EJ. Antimicrobial drug resistance in Salmonella: problems and perspectives in food- and water-borne infections. FEMS Microbial Rev 2002 26:141-8.
(22.) Kiessling CR, Cutting JH, Loftis M, Kiessling WM, Datta AR, Sofos JN. Antimicrobial resistance of food-related Salmonella isolates, 1999-2000. J Food Protect 2002;65:603-8.
(23.) Baggesen DL, Sandvang D, Aarestrup FM. Characterization of Salmonella enterica serovar Typhimurium DT104 isolated from Denmark and comparison with isolates from Europe and the United States. J Clin Microbial 2000;38:1581-6.
(24.) National Committee for Clinical Laboratory Standards. Performance standards for antimicrobial susceptibility testing: twelfth informational supplement. M100-S12. Wayne (PA); The Committee; 2002.
(25.) Bopp CA, Brenner FW, Wells JG, Strockbine NA. Escherichia, Shigella, and Salmonella. In: Murray PR, Baron EJ, Pfaller MA, Tenover FC, Yolken RH, editors. Manual of clinical microbiology, 7th ed. Washington: American Society for Microbiology; 1999 p. 459-74.
(26.) National Committee for Clinical Laboratory Standards. Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically; approved standards. 5th edition. M7-A4. Wayne (PA); The Committee; 2000.
(27.) Giraud E, Brisabois A, Martel JL, Chaslus-Dancla E. Comparative studies of mutations in animal isolates and experimental in vitro- and in vivo-selected mutants of Salmonella spp. suggest a counter selection of highly fluoroquinolone-resistant strains in the field. Antimicrob Agents Chemother 1999;43:2131-7.
(28.) Giraud E, Cloeckaert A, Kerboeuf D, Chaslus-Dancla E. Evidence for active efflux as the primary mechanism of resistance to ciprofloxacin in Salmonella enterica serotype Typhimurium. Antimicrob Agents Chemother 2000;44:1223-8.
(29.) Wang H, Dzink-Fox JL, Chen M, Levy SB. Genetic characterization of highly fluoroquinolone-resistant clinical Escherichia coli strains from China: role of acrR mutation. Antimicrob Agents Chemother 2001;45:1515-21.
(30.) Piddock LJ, White DG, Gensberg K, Pumbwe L, Griggs DJ. Evidence for an efflux pump mediating multiple antibiotic resistance in Salmonella enterica serovar Typhimurium. Antimicrob Agents Chemother 2000;44:3118-21.
(31.) Liebana E, Clouting C, Cassar CA, Randall LP, Walker RA, Threlfall EJ, et al. Comparison of gyrA mutations, cyclohexane resistance, and the presence of class 1 integrons in Salmonella enterica from farm animals in England and Wales. J Clin Microbiol 2002;40:1481-6.
(32.) Tamada Y, Nakaoka Y, Nishimori K, Doi A, Kumaki T, Uemura N, et al. Molecular typing and epidemiological study of Salmonella enterica serotype Typhimurium isolates from cattle by fluorescent amplified-fragment length polymorphism fingerprinting and pulsed-field gel electrophoresis. J Clin Microbiol 2001;39:1057-66.
(33.) Tenover FC, Arbeit R, Goering RV, Mickelsen PA, Murray BE, Persing DH, et al. interpreting chromosomal DNA restriction patterns produced by pulsed-field gel electrophoresis: criteria for bacterial strain typing. J Clin Microbial 1995;33:2233-9.
(34.) Su LH, Chiu CH, Kuo AJ, Chia JH, Sun CF, Leu HS, et al. Secular trends in incidence and antimicrobial resistance among clinical isolates of Salmonella at a university hospital in Taiwan, 1993-1999. Epidemiol Infect 2001;127:207-13.
(35.) Hooper DC. Emerging mechanisms of fluoroquinolone resistance. Emerg Infect Dis 2001;7:337-41.
(36.) Tran JH, Jacoby GA. Mechanism of plasmid-mediated quinolone resistance. Proc Natl Acad Sci U S A 2002;99:5638-42.
(37.) Randall LP, Woodward MJ. Multiple antibiotic resistance (mar) locus in Salmonella enterica serovar Typhimurium DT104. Appl Environ Microbiol 2001:67:1190-7.
(38.) Zgurskaya HI, Nikaido H. Multidrug resistance mechanisms: drug efflux across two membranes. Mol Microbiol 2000;37:219-25.
(39.) Poole K. Efflux-mediated resistance to fluoroquinolones in gram-negative bacteria. Antimicrob Agents Chemother 2000;44:2233-41.
(40.) Engberg J, Aarestrup FM, Taylor DE, Gerner-Smidt P, Nachamkin I. Quinolone and macrolide resistance in Campylobacter jejuni and C. coli: resistance mechanisms and trends in human isolates. Emerg Infect Dis 2001;7:244.
(41.) Mcdonald LC, Chen MT, Lauderdale TL, Ho M. The use of antibiotics critical to human medicine in food-producing animals in Taiwan. I Microbiol Immunol Infect 2001;34:97-102.
(42.) Li CC, Chin CH, Wu JL, Huang YC, Lin TY. Antimicrobial susceptibility of Campylobacter jejuni and call by using E-test in Taiwan. Scand J Infect Dis 1998;30:39-42.
Dr. Hsueh is an associate professor in the Departments of Laboratory Medicine and Internal Medicine, National Taiwan University Hospital, National Taiwan University College of Medicine. His research interests include mechanisms of antimicrobial resistance and molecular epidemiology of emerging pathogens. He is actively involved in a national research program for antimicrobial drug resistance, Surveillance for Multicenter Antimicrobial Resistance (SMART) in Taiwan.
Address for correspondence: Po-Ren Hsueh, Department of Laboratory Medicine, National Taiwan University Hospital, No. 7 Chung-Shan South Road, Taipei, Taiwan; fax: 886-2-23224263; email: hsporen@ ha.mc.ntu.edu.tw
Po-Ren Hsueh, * ([dagger]) Lee-Jene Teng, * ([dagger]) Sung-Pin Tseng, * Chao-Fu Chang, ([double dagger]) Jen-Hsien Wan, ([dagger]) Jing-Jou Yan, ([dagger]) Chun-Ming Lee, ([dagger]) Yin-Ching Chuang, ([dagger]) Wen-Kuei Huang, ([dagger]) Dine Yang, ([dagger]) Jainn-Ming Shyr, ([dagger]) Kwok-Woon Yu, ([dagger]) Li-Shin Wang, ([dagger]) Jang-Jih Lu, ([dagger]) Wen-Chien Ko, ([dagger]) Jiunn-Jong Wu, ([dagger]) Feng-Yee Chang, ([dagger]) Yi-Chueh Yang, ([dagger]) Yeu-Jun Lau, ([dagger]) Yung-Ching Liu, ([dagger]) Cheng-Yi Liu, ([dagger]) Shen-Wu Ho, ([dagger]) and Kwen-Tay Luh * ([dagger])
* National Taiwan University College of Medicine, Taipei, Taiwan; ([dagger]) The Study Group of Surveillance from Multicenter Antimicrobial Resistance in Taiwan, Taipei, Taiwan; and ([double dagger]) Graduate Institute of Veterinary Medicine, National Taiwan University, Taipei, Taiwan
COPYRIGHT 2004 U.S. National Center for Infectious Diseases
COPYRIGHT 2004 Gale Group